IPG makes industrial lasers. In 2025 about 86% of sales came from factory work like cutting and welding, with medical, science, chip-making and defence about 7% each.
The company · 2 · What exactly does it sell?
High-power lasers lead a mixed range
Each $1 of sales, 2025
31%26%15%14%9%5%
High-power lasersParts, service and otherComplete systemsPulsed lasersMedium-power lasersOther continuous lasers
Ordinary cutting lasers are bought mostly on price; the newer lines sell on performance.
The company · 3 · How does it make money?
It sells lasers to factories, mostly on price
$926Mof cash and investments, and no debt
29%of its lasers sold in China
About 60%fall in a standard laser's price, 2018 to 2024
Factories buy lasers when they invest, so sales follow the industrial cycle.
Is it a good business? · 4 · What gives it an edge?
Its cost edge faded as rivals grew
$207K vs $238K
sales per employee, 2025 against 2016
Raycus
now leads in China
Making every key part in-house, chips to fibre, once made IPG the cheapest; Chinese rivals caught up.
Is it a good business? · 5 · What is the catch?
Cheaper Chinese lasers, and defence rivals ahead
Raycusnow outsells IPG in China
AeroVironmentwon the Army's first laser-weapon order
Is it a good business? · 6 · What does its record show?
Sales fell a third and profit collapsed
Sales, $B
1.5
1.4
1.3
1.0
1.0
1.1
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$1.46B → $1.11Bsales, 2021 to the past year
Profit25% → 1.9%operating profit per $1
Kept48% → 39%kept per $1 after making it
Research, selling and office spending did not fall with sales, so a recovery widens profit fast.
Is it a good business? · 7 · How much room is there to grow?
The drone-laser market cannot be sized yet
About $790MPentagon request for energy weapons, 2025
$1.1Bthe year before, so falling
26Army lasers in the one production contract
Nobody publishes how many small drone lasers are bought a year, so IPG's slice is unknown.
Is it a good business? · 8 · Who is in charge?
A new chief from a rival laser group
Mid-2024Mark Gitin became chief executive
34.7%of shares voted by Eugene Scherbakov through the founder's trusts
Since 2000Tim Mammen, finance chief
The founder's family trusts still hold a large block of votes.
The story right now · 9 · Why did laser profits collapse?
Chinese makers cut laser prices hard
About 60%standard laser price fall
25% → 1.9%IPG's operating profit per $1
Chinese laser makers grew fast and cut prices to win factories at home and abroad. IPG had to follow, and its profit per sale fell sharply. Chinese battery demand is also cooling.
The story right now · 10 · Can IPG earn like it used to?
Profit returns only if prices hold
Sales recoverUp 15%.
Fixed costs spreadProfit widens.
Chinese prices stay lowCaps what each sale keeps.
Target unprovenMid-40s kept per $1.
Management aims to keep mid-40s cents per $1; it kept about 39 cents without help in September.
The story right now · 11 · What changed lately?
Sales up 15% and profit per sale held
$287.5Msales in the September quarter
+33%growth in defence and chips
41.0%kept per $1, helped by tariff refunds
37% to 40%kept per $1 expected next quarter
Solid quarter
IPG's purchase of Lumibird should close by year end; Chinese battery demand is cooling.
The story right now · 12 · What is everyone arguing about?
On the way back, or priced for it?
Many investors think
A cyclical laser maker on the way back
We think
The recovery is priced in and profit unproven
The defence line is small while rivals win the big contracts.
The price and our view · 13 · What is a share worth?
The price sits near our sunny case
$44.24what we think a share is worth · the last close is of that
$44.24our value
Attractive below $35.39
Neutral
Unattractive above $53.09
$25.21gloomy: Chinese price cuts keep profit thin
$44.24our estimate: experts' path, then slowing
$68.16sunny: new lines grow, profit reaches 15%
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Chinese prices and a cooling cycle
Chinese price cutsBiggest
Cap what each sale keeps.
Battery demand coolsShowing now
China slows.
Defence rivals aheadWatch
They win big orders.
Drone-laser demandUnknown
Nobody counts it.
Ordinary cutting lasers are bought mostly on price.
The price and our view · 15 · How will we know?
February tests profit per sale
Kept per $1 near 40% without refundsGood sign
Defence orders growGood sign
Chinese prices fall againBad sign
FEB 202711
Fourth-quarter 2026 results, 11 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
A cash-rich laser maker priced for a recovery
$44.24our value
Attractive below $35.39
Neutral
Unattractive above $53.09
UnattractiveMedium conviction
IPG makes industrial lasers and holds plenty of cash with no debt. But Chinese rivals cut prices so hard that its operating profit fell from about a quarter of sales to about 2%, and the price pays for a return.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
IPG Photonics makes fiber lasers: light produced inside a thin strand of glass and delivered down a flexible cable. Factories use them to cut sheet metal, weld car bodies and batteries, mark parts and clean surfaces. The buyer is usually a company that builds cutting or welding machines and puts IPG's laser inside.
IPG makes the key parts itself, from the light-producing chips to the glass fibre. Its lead today is in the most powerful and precise lasers; ordinary cutting lasers have become a product bought mostly on price.
How it makes money
IPG earns money selling lasers and laser systems to machine builders and manufacturers. In 2025 about 86% of sales came from factory work like cutting and welding, about 7% from medical lasers and about 7% from science, chip-making and defence, where the drone laser sits.
Orders are short: the year-end backlog was about seven months of sales, mostly cancellable. Buying Lumibird Medical, an eye-laser maker, adds about an eighth to sales.
Growth and profit
What growth costs
IPG's research, sales and office costs barely moved when sales fell, so profit margins collapsed. The flip side is that growth should rebuild them: each extra sale needs little extra overhead, and the latest year started to show that. Pay in shares is creeping up.
Its record
The numbers
Is it growing?Steady
Sales grew 15% over the twelve months to Sep 2026, faster than the 2.7% in the year to Dec 2025.
Is it profitable?Thin
Operating margin is 1.9%, down from 18% in the year to Dec 2023.
Does growth pay off?Pays off
Running costs take 37¢ of each sales dollar, up from 22¢ in the year to Dec 2021.
Does it earn good returns?Low
Each dollar put into the business earns 0.8% a year after tax, down from 10% in the year to Dec 2021.
Is it making cash?Thin
It turned 3.2% of sales into free cash, $35.0M over the last twelve months.
How steady is it?Swingy
Yearly sales growth has ranged from −24% to +22% over the last 5 years, with sales falling in 3 of them.
Are shares being diluted?Shrinking
The share count fell 21% in 4.8 years, and pay in shares costs 3.8% of sales.
Why it wins
The evidence
IPG's protection was supposed to be cost: making every part itself should let it build a laser more cheaply than anyone. That held while it was far bigger than its rivals. It no longer is.
In China, which buys about 29% of IPG's lasers, the local leader Raycus now outsells IPG, and the price of a standard laser fell about 60% between 2018 and 2024. Sales per IPG employee are lower than in 2016. Customers come back for IPG's best lasers; for ordinary ones they shop on price.
Who could beat it
The rivals in full
In factories the threat is Chinese makers like Raycus, selling similar lasers for much less, and Germany's Trumpf, whose patents a European court found IPG's welding lasers infringed; IPG paid to settle.
In defence, rivals are further ahead. The US Army's first production order for laser weapons went to AeroVironment, and nLight already sells far more laser equipment to the military than IPG.
Each rival
Wuhan Raycus Fiber Laser Technologies300747.SZ
the buyer fits a Raycus continuous-wave laser into the same cutting or welding machine at a much lower price per kilowatt
the marking and micromachining laser, where JPT sells pulsed fiber lasers to the same Chinese machine builders
Trumpf disc and fiber lasersprivate
the welding laser in automotive and battery lines, where Trumpf sells both the laser and the machine; a European court found IPG's adjustable-mode lasers infringed Trumpf patents
the laser inside other makers' weapons: nLight sells the source to defence primes and grew that business 60% in 2025
Lockheed Martin's own high-energy lasersLMT
the larger air-defence laser, where Lockheed builds 300-kilowatt systems itself and is IPG's only named CROSSBOW customer
How big it could get
The market and who has signed
The market
The Pentagon asked for about $790M for all laser and other energy weapons in its 2025 budget, down from $1.1B the year before, and most of that pays for research on large weapons.
The one production contract so far buys 26 army lasers over five years, each 30 kilowatts against IPG's 3. Nobody publishes how many small drone lasers are bought a year, so IPG's market cannot be sized; it is a slice of that budget.
Who has signed
One defence customer has signed: Lockheed Martin ordered about $10M of CROSSBOW systems in February 2026, shipping over several quarters. No second buyer has been named.
For lasers in general, about a third of the year-end backlog was non-binding frame agreements rather than firm orders.
Who runs it
Leaders, pay and the cash
Who runs it
Mark Gitin, hired from a rival laser group, has run IPG since mid-2024; Tim Mammen has been finance chief since 2000. The founder's trusts still control about a third of the votes, through directors acting as trustees, and they have been selling. Gitin owns little himself. His bonus rides on sales and profit, his shares on growth in sales and profit and on tight stock and receivables, none on how much profit each dollar invested earns.
The last report
The latest report
IPG's sales rose 15% and margin held near 39% without tariff refunds
What it did to the thesis Solid quarter
It met the test we set: sales and the margin without refunds both cleared the line. That supports the recovery without proving it, because the margin is still short of management's target and next quarter's guide is lower.
The report
Sales grew 15% to $287.5M in the September quarter, led by welding lasers and additive manufacturing. The part holding defence and chips grew 33%. On the call, management said chip sales more than doubled and most of one large Lockheed Martin order shipped in the quarter; it called defence lumpy.
Gross margin was 41.0%, about 39.2% without $5.0M of tariff refunds, as in June. Next quarter's margin was guided lower, to 37% to 40%, and Chinese battery demand is cooling, which the guide allows for.
What's happening now
The background
The shares jumped 35% in one day in February 2026, on the report that first featured the drone laser, then fell back, and closed at $70.11 on 4 November, 17% below 2 October. That took the business, counting Lumibird, to about twice a year's sales, the line we set for attractive.
September-quarter results on 3 November passed the first test of the margin without the refund. Lumibird should close by year end, and the fourth-quarter guide, a margin of 37% to 40%, is the next test.
Where we disagree
Both sides in full
The market
A cyclical laser maker on the way back, with a defence business as a bonus.
We believe
The recovery is mostly priced in, the margin target is unproven against Chinese prices, and the defence line is too small to matter yet.
The argument
Most analysts rate the shares a buy, expecting sales and profit to recover strongly in 2027.
We think the factory recovery is real but the margin is the open question: management still aims for a gross margin in the mid-40s, and it was about 39% without help in September. And the defence line is small while rivals win the big contracts.
We could be wrong if the margin climbs past 43% on its own, or a second drone-laser customer signs.
What it's worth
How we value it
A laser maker recovering from a price war is valued on its own recent growth, with Lumibird Medical's sales added and its cost taken from the cash, and a GAAP margin after stock pay recovering to management's plan, slowing toward 4% by year ten, each year closing 30% of the gap.
The three cases
Bear case$25.21
Chinese rivals keep cutting prices (C19): growth slows to 6% then 4%, the margin recovers only to 6%, near Q3 2026's 7.2%, and new capital earns only its 9% cost.
Our value$44.24
2025 sales of $1,004M plus Lumibird Medical's roughly $130M grow 10% in 2026, the year to September having grown 10% with Q3 up 15% (C51); then 10% and 8%; the GAAP operating margin, after stock pay, recovers from 1.9% to 12%, about management's plan and 2022's 11.9% (C05, C25).
Bull case$68.16
Medical, semiconductor and defence sales keep the 15% pace of Q3 2026 (C51) for two years and the margin climbs to 15%, still below 2023's 18% (C05).
The bet
Seen as a bet
The bet is on IPG Defense, the drone-killing laser. The factory and medical business is counted separately at the price the whole company sells for now.
If several customers buy at Lockheed's pace each year, the shares are worth only slightly more than today, because the defence line is so small next to the rest. If CROSSBOW comes to nothing, the factory business and the cash still cover roughly today's price, so little is lost.
What could go wrong
Every risk
The risks
China's price war
Chinese rivals cut laser prices about 60% in six years and now outsell IPG in China, which buys 29% of its lasers.
The margin may not return
Without one-off tariff refunds the margin was about 39% in both June and September, short of the mid-40s target, and the next quarter is guided lower.
Cash spent at full price
Lumibird Medical takes about $349M of the cash at roughly the price IPG itself trades at, so it adds little unless its margins rise.
Defence is going elsewhere
Defence sales fell in both 2026 quarters, and the army's first production contract went to a far more powerful rival laser.
Patents
European courts found IPG's adjustable-beam welding lasers infringed Trumpf patents; IPG settled and now pays Trumpf a royalty to keep selling them.
What we still do not know
How much IPG sells to the military: it reports defence inside a larger line and never gives the figure.
What one CROSSBOW system costs, and how many the $10M Lockheed order bought.
Whether Chinese makers, now exporting, will push prices down in Europe and America as they did at home.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $53.09, 20% above what we think the business is worth.
→ Attractive
The share price falls to about $35.39, 20% below what we think the business is worth.
The next test
It supports the case if
Adjusted gross margin at or above 39.0% excluding refunds, revenue at or above $280M before Lumibird, and Advanced Solutions up on the year.
It pressures the case if
Adjusted gross margin below 39.0% excluding refunds, or revenue below $265M before Lumibird, or Advanced Solutions down on the year; a margin below 37% for a second quarter points to Unattractive.
We would also be wrong if
Operating margin returns above 15% within two years with Chinese prices stable.
A second CROSSBOW customer places a disclosed order by the end of 2027.
The verdict
Scores and how we weighed it
The scores
Growth
2 of 4
Business quality
2 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
3 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value, which already assumes the margin recovers.
BusinessMixed
A mixed business: cash and no debt, but a margin crushed by a price war.
GrowthMixed
Sales and the margin cleared our line, but the guide is lower.
RisksNegative
China's price war continues, the margin may not return and cash went to a purchase at full price.
RivalsMixed
No filed rival compares directly; its history was earned at far higher margins.
The groupMixed
Optical names move together on AI spending news.
Latest newsPositive
The last report met the test we set.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.